The dissemination program AmgenTransferCičncia brings biotechnology and genetics to Valencian institutes

Víctor Garrigós and Belén Llobregat.
Víctor Garrigós and Belén Llobregat.
The educational program to promote scientific vocations AmgenTransferCičncia arrives this Thursday, March 30 and Friday, March 31 at IES l’Eliana and IES Nůmero 26 Misericérdia in Valencia. It is a program with lectures and experimentation workshops in biotechnology and genetics given by young researchers.

Specifically, Victor Garrigòs, from the Institute of Integrative Systems Biology (I2Sysbio), a joint centre of the University of Valencia (UV) and the Spanish National Research Council (CSIC), will participate in l’Eliana, and in Valencia Belén Llobregat, from the Institute of Agrochemistry and Food Technology (IATA), located in the UV Science Park. Both acts will deal with the detection of genetically modified organisms (GMOs) by PCR.

These promotional actions are offered in five Valencian institutes between February and May of this year. The last Valencian centre to participate will be IES Distrito Marítimo, which on May 18 will host I2Sysbio researcher Cecilia Picazo, who will teach a practice on the extraction and amplification of DNA from biological remains with a game to identify the author of a supposed crime AmgenTransferCičncia started as a pilot program in the 2019-2020 academic year. Currently, 35 schools from the Valencian Community, Madrid, the Balearic Islands, Catalonia and Galicia participate, with more than 875 students.

The Catalan Foundation for Research and Innovation (FCRI), born in 1986, disseminates research and innovation among society to promote scientific culture, scientific-technical vocations among young people and entrepreneurship and public-private collaboration in R + D. Amgen is a biopharmaceutical company dedicated to the development and production of biological medicines for patients with serious diseases or unmet medical needs. With the objective of improving the quality of life of the sick, it focuses its efforts on cardiology, nephrology, bone health and oncohematology. Its treatments have benefited more than 20 million patients worldwide and hundreds of thousands of people in Spain, where it has been present since 1990.

Activity in Teulada and Alaquŕs

This edition of the project started in the Valencian territory last February 8 at IES Teulada with Luis Orduńa (I2Sysbio); and on February 14 at the IES Faustí Barberŕ of Alaquŕs with Borja Sáez, from the Institute of Biomedicine of Valencia (IBV-CSIC), who carried out a practice on pGLO bacterial transformation.